Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan

Abstract

Among chronic liver diseases, fatty liver has the highest incidence worldwide. Coexistence of fatty liver and other chronic diseases, such as diabetes, hepatitis B virus (HBV) and Helicobacter pylori (Hp) infection, is common in clinical practice. The present study was conducted to analyze the prevalence and association of coexisting diseases in patients with fatty liver and to investigate how coexisting diseases contribute to abnormal transaminase and lipid profiles. We enrolled participants who were diagnosed with fatty liver via ultrasound in the physical examination center of West China Hospital. Multivariable logistic regression was used to determine the adjusted odds ratios (ORs). We found that 23.6% of patients who underwent physical examinations were diagnosed with fatty liver. These patients had higher risks of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), and hypertension and a lower risk of HBV infection. The risks of Hp infection and hyperthyroidism did not statistically differ. When fatty liver coexisted with T2DM, MetS and thyroid dysfunction, it conferred a higher risk of elevated transaminase. Fatty liver was positively correlated with triglycerides, cholesterol and low-density lipoprotein cholesterol (LDL-C) and negatively correlated with HBV; thus, HBV had a neutralizing effect on lipid metabolism when coexisting with fatty liver. In conclusion, patients with fatty liver that coexists with T2DM, MetS and thyroid dysfunction are more prone to elevated transaminase levels. Patients with both fatty liver and HBV may experience a neutralizing effect on their lipid metabolism. Thus, lipid alterations should be monitored in these patients during antiviral treatment for HBV.

The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients

“…Therefore, it is challenging to determine patients with a high risk of progression. Recent guidelines suggested a screening system for NAFLD including the use of liver function biomarkers, and variable indices (Giri et al 2022 ; Jiang et al 2021 ; Tokushige et al 2021 ; Kang et al 2021 ). AST/ ALT ratio, TyG index, FLI, and HIS reflected NAFLD in our groups with variable percentages (AST/ALT: 64 versus 56%; TyG index: 92 versus 76%; FLI: 84 versus 64%; HSI: 88 versus 64% in fatty and non-fatty liver groups; respectively).…”

Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis

“…The above studies all suggest that the prevalence of NAFLD in HBsAg-positive population is lower, which may be related to the involvement of HBV in lipid metabolism in the liver. It was found that HS was positively correlated with the level of triglyceride and low-density lipoprotein cholesterol (LDL-C) and negatively correlated with HBV infection, suggesting that HBV may have the effect of neutralizing lipid metabolism [ 19 ]. Results of a Korean cohort study of non-cirrhotic and non-diabetic adults (n = 62,287) with a 4.46-year follow-up showed that serum HBsAg positivity was negatively correlated with development of hypercholesterolemia, high LDL-C triglyceride, and high non-high-density lipoprotein-cholesterol (non-HDL-C) (aHR = 0.71, 95%CI 0.64–0.79; 0.83 [0.78–0.89]; 0.61 [0.54–0.70]; 0.69 [0.63–0.75]; respectively) [ 20 ].…”